睿知中国医院研究地图
候选清单

正在招募B 细胞急性淋巴细胞白血病I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

ClinicalTrials.gov 上登记的一项B 细胞急性淋巴细胞白血病开放试验,由北京大学人民医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方北京大学人民医院Peking University People's Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06880913,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 12 岁 至 65 岁;性别:不限

    登记记录的入选字段

  2. Flow cytometry confirms CD19 or CD22 positivity in tumor cells from bone marrow, peripheral blood, or cerebrospinal fluid, or pathology confirms CD19 or CD22 positivity in lymph nodes/masses or extranodal lesions.

    入选标准第 2 条

  3. Eligibility for Phase II (RP2D) is restricted to patients with R/R B-ALL who have failed prior immunotherapies, including blinatumomab, inotuzumab ozogamicin, or prior single-target CAR-T therapy.

    入选标准第 3 条

    Receipt of extensive radiotherapy within 4 weeks prior to signing the ICF, except for palliative radiotherapy for non-target lesions within 2 weeks before signing the ICF or as expected during the study.

    排除标准第 39 条

    Unresolved toxicity from prior antitumor therapy that has not returned to Grade 1 or baseline levels at the time of signing the ICF, except for hair loss and pigmentation (per NCI-CTCAE v5.0).

    排除标准第 40 条

    Major surgery within 4 weeks prior to signing the ICF (excluding routine biopsy procedures) or planned major surgery during the study period.

    排除标准第 46 条

  4. Bone marrow morphological examination at screening shows >5% blasts in the bone marrow, and/or cerebrospinal fluid (CSF) analysis detects leukemic cells, and/or the presence of measurable extramedullary lesions, defined as:

    入选标准第 1 条

  5. Hepatitis B virus (HBV): Subjects with positive HBsAg or HBcAb-positive at screening must have undetectable HBV DNA in peripheral blood to be eligible; otherwise, they should be excluded.

    排除标准第 20 条

    Hepatitis C virus (HCV): Subjects with positive HCV antibodies and detectable HCV RNA should be excluded.

    排除标准第 21 条

    Human immunodeficiency virus (HIV) antibody-positive subjects should be excluded.

    排除标准第 22 条

    History of other primary malignancies within 5 years prior to signing the ICF, except for:

    排除标准第 48 条

  6. Pregnancy or lactation.

    排除标准第 53 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力;化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06880913,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Bone marrow morphological examination at screening shows >5% blasts in the bone marrow, and/or cerebrospinal fluid (CSF) analysis detects leukemic cells, and/or the presence of measurable extramedullary lesions, defined as:
  2. Flow cytometry confirms CD19 or CD22 positivity in tumor cells from bone marrow, peripheral blood, or cerebrospinal fluid, or pathology confirms CD19 or CD22 positivity in lymph nodes/masses or extranodal lesions.
  3. Eligibility for Phase II (RP2D) is restricted to patients with R/R B-ALL who have failed prior immunotherapies, including blinatumomab, inotuzumab ozogamicin, or prior single-target CAR-T therapy.
  4. Liver function:
  5. Renal function:

排除标准:Exclusion Criteria:

  1. History of central nervous system (CNS) diseases, including but not limited to:
  2. Epilepsy
  3. Paralysis
  4. Aphasia
  5. Stroke
  6. Severe brain injury
  7. Dementia
  8. Parkinson's disease
  9. Neuropathy
  10. History of autoimmune diseases requiring systemic immunosuppressive therapy within 2 years prior to signing the ICF, including but not limited to:
  11. Crohn's disease
  12. Rheumatoid arthritis
  13. Systemic lupus erythematosus (SLE)
  14. Systemic sclerosis
  15. Inflammatory bowel disease (IBD)
  16. Vasculitis
  17. Psoriasis
  18. Presence of any uncontrolled active infection at the time of signing the ICF or within 4 weeks prior to apheresis that requires antibiotic, antiviral, or antifungal treatment.
  19. Positive virological or infectious disease markers, including:
  20. Hepatitis B virus (HBV): Subjects with positive HBsAg or HBcAb-positive at screening must have undetectable HBV DNA in peripheral blood to be eligible; otherwise, they should be excluded.
  21. Hepatitis C virus (HCV): Subjects with positive HCV antibodies and detectable HCV RNA should be excluded.
  22. Human immunodeficiency virus (HIV) antibody-positive subjects should be excluded.
  23. Cytomegalovirus (CMV) DNA test-positive subjects should be excluded.
  24. Epstein-Barr virus (EBV) DNA test-positive subjects should be excluded.
  25. Positive serological or non-specific antibodies for Treponema pallidum (syphilis).
  26. Clinically significant cardiovascular diseases, including any of the following:
  27. QTc interval ≥480 ms (Fridericia correction formula)
  28. New York Heart Association (NYHA) Class II or higher heart failure
  29. Unstable angina or acute myocardial infarction within 6 months prior to signing the ICF
  30. Left ventricular ejection fraction (LVEF) <50%
  31. Poorly controlled hypertension (as determined by the investigator)
  32. Clinically significant arrhythmias or those requiring antiarrhythmic treatment, including:
  33. Persistent ventricular tachycardia
  34. Ventricular fibrillation
  35. Torsades de pointes
  36. Complete left bundle branch block
  37. History of severe hypersensitivity or allergy to any components of the study drug.
  38. Receipt of any investigational drug therapy or other systemic antitumor therapy within 4 weeks before apheresis (or 5 half-lives of the drug, whichever is longer, as determined by the investigator).
  39. Receipt of extensive radiotherapy within 4 weeks prior to signing the ICF, except for palliative radiotherapy for non-target lesions within 2 weeks before signing the ICF or as expected during the study.
  40. Unresolved toxicity from prior antitumor therapy that has not returned to Grade 1 or baseline levels at the time of signing the ICF, except for hair loss and pigmentation (per NCI-CTCAE v5.0).
  41. Requirement for systemic corticosteroids or other immunosuppressive therapy (≥10 mg/day prednisone or equivalent) within 3 days prior to apheresis or during the study period, except for:
  42. Intranasal, inhaled, or topical steroids, or localized steroid injections (e.g., intra-articular injections)
  43. Systemic corticosteroids ≤10 mg/day prednisone (or equivalent physiological dose)
  44. Steroids as prophylaxis for allergic reactions (e.g., pre-medication before contrast-enhanced CT)
  45. Steroids used for symptomatic treatment of transfusion-related reactions
  46. Major surgery within 4 weeks prior to signing the ICF (excluding routine biopsy procedures) or planned major surgery during the study period.
  47. History of active tuberculosis infection within 1 year prior to signing the ICF, except for subjects with a history of tuberculosis more than 1 year ago, provided that the investigator determines there is no evidence of active tuberculosis.
  48. History of other primary malignancies within 5 years prior to signing the ICF, except for:
  49. Adequately treated carcinoma in situ of the cervix
  50. Localized basal cell carcinoma or squamous cell carcinoma of the skin
  51. Receipt of live-attenuated or inactivated vaccines within 4 weeks before signing the ICF or planned vaccination during the screening period.
  52. Any other condition or complication that, in the investigator's judgment, may affect adherence to the study protocol or make the subject unsuitable for participation.
  53. Pregnancy or lactation.

引自 ClinicalTrials.gov, NCT06880913, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06880913,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06880913